Verona Pharma plc (NASDAQ:VRNA) Q3 2024 Earnings Call Transcript
Q3 2024 Earnings Call Transcript November 4, 2024 Verona Pharma plc beats earnings expectations. Reported EPS is $-0.08819, expectations were $-0.5. Operator: Good morning, everyone, and welcome to Verona Pharma’s Third Quarter 2024 Financial Results and Operating Highlights Conference Call.
Verona Pharma (NASDAQ:VRNA) shareholder returns have been incredible, earning 724% in 5 years
Verona Pharma isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip. As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth.
David Zaccardelli Sells 4,800 Shares of Verona Pharma plc (NASDAQ:VRNA) Stock
CEO David Zaccardelli sold 4,800 shares of Verona Pharma stock in a transaction that occurred on Friday, October 25th. The stock was sold at an average price of $4.38, for a total transaction of $21,024.
Recent Price Trend in Verona Pharma (VRNA) is Your Friend, Here's Why
Verona Pharma (VRNA) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Verona Pharma plc (VRNA) Q3 2024 Earnings Call Transcript
Q3 2024 Earnings Conference Call November 4, 2024 9:00 AM ETCompany ParticipantsDavid Zaccardelli - President and
Verona Pharma Reports Strong Q3 Launch for COPD Drug
Verona Pharma ( (VRNA) ) has released its Q3 earnings. Here is a breakdown of the information Verona Pharma presented to its investors. Verona
Raleigh pharma's stock hits record high amid drug launch
Verona Pharma's market cap nears $3 billion after drug launch. Ohtuvayre sales reached $5.6 million in the third quarter. Over 5,000 Ohtuvayre prescriptions filled by October's end. A Raleigh biopharmaceutical company is nearing a $3 billion market capitalization amid the launch of its lead drug.
Verona Pharma Receives Buy Rating Amid Strong Financial Performance and Growth Prospects
Analyst Ram Selvaraju of H.C. Wainwright reiterated a Buy rating on Verona Pharma (VRNA – Research Report), boosting the price target to ...
Verona Pharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Ohtuvayre™ (ensifentrine) launch recorded Q3 net sales of $5.6 million and October net sales exceeded Q3 Through October more ...
ETF Daily News9d
Verona Pharma plc (NASDAQ:VRNA) Shares Sold by PFG Investments LLC
Get Our Latest Analysis on VRNA Verona Pharma Trading Down 1.7 % Shares of Verona Pharma stock opened at $33.86 on Monday. The company has a current ratio of 8.61, a quick ratio of 8.61 and a ...
Business Insider21h
Verona Pharma (VRNA) Receives a Buy from Truist Financial
Truist Financial analyst Joon Lee maintained a Buy rating on Verona Pharma (VRNA – Research Report) today. The company’s shares closed yesterday at $38.15. According to TipRanks, Lee is a 5-star ...
FiercePharma8d
After prior trial flop, EyePoint's Duravyu bounces back with promising data in DME
Earlier this year, EyePoint Pharmaceuticals’ drug-device combo Duravyu missed the mark in a non-proliferative diabetic ...
Investing4d
Verona Pharma PLC ADR (VRNA)
At the close in NYSE,... ByInvesting.com • Mar 26, 2018 Verona Pharma's RPL554 shows treatment effect in mid-stage CF study; shares up 8% A UK-based Phase 2a clinical trial evaluating Verona ...
Yahoo Finance12d
Zacks Industry Outlook Highlights Exelixis, Blueprint Medicines, CRISPR, Amicus and Verona Pharma
Companies in this volatile biotech industry continue to be in the spotlight as pharma/biotech goliaths are looking to bolster their product portfolios and pipelines through collaborations and ...